Current Trends of Practices in Nonclinical Toxicology: An Industry Survey

The growth in drug development over the past years reflects significant advancements in basic sciences and a greater understanding of molecular pathways of disease. Benchmarking industry practices has been important to enable a critical reflection on the path to evolve pharmaceutical testing, and the outcome of past industry surveys has had some impact on best practices in testing. A survey was provided to members of SPS, ACT, and STP. The survey consisted of 37 questions and was provided to 2550 participants with a response rate of 24%. Most respondents (∼75%) came from the US and Europe. The survey encompassed multiple topics encountered in nonclinical testing of pharmaceuticals. The most frequent target indications were oncology (69%), inflammation (55%), neurology/psychiatry/pain (46%), cardiovascular (44%), and metabolic diseases (39%). The most frequent drug-induced toxicology issues confronted were hepatic, hematopoietic, and gastrointestinal. Toxicological effects that impacted the no observed adverse effect level (NOAEL) were most frequently based on histopathology findings. The survey comprised topics encountered in the use of biomarkers in nonclinical safety assessment, most commonly those used to assess inflammation, cardiac/vascular, renal, and hepatic toxicity as well as common practices related to the assessment of endocrine effects, carcinogenicity, genotoxicity, juvenile and male-mediated developmental and female reproductive toxicity. The survey explored the impact of regulatory meetings on program design, application of the 3 Rs, and reasons for program delays. Overall, the survey results provide a broad perspective of current practices based on the experience of the scientific community engaged in nonclinical safety assessment.

1. Mullard, A . 2020 FDA drug approvals. Nat Rev Drug Discov. 2021;2:85-90.
Google Scholar | Crossref2. Torre, BG, Albericio, F. The Pharmaceutical Industry in 2020. An Analysis of FDA Drug Approvals from the Perspective of Molecules. Molecules. 2021;26(3). doi:10.3390/molecules26030627
Google Scholar | Crossref3. Purves, D, Harvey, C, Tweats, D, Lumley, CE. Genotoxicity testing: current practices and strategies used by the pharmaceutical industry. Mutagenesis. 1995;10(4):297-312. doi:10.1093/mutage/10.4.297
Google Scholar | Crossref | Medline4. Morgan, SJ, Couch, J, Guzzie-Peck, P, et al. Regulatory forum opinion piece. Toxicol Pathol. 2017;45(3):372-380. doi:10.1177/0192623317701004
Google Scholar | SAGE Journals | ISI5. Prior, H, Bottomley, A, Champéroux, P, et al. Social housing of non-rodents during cardiovascular recordings in safety pharmacology and toxicology studies. J Pharmacol Toxicol Methods. 2016;81:75-87. doi:10.1016/j.vascn.2016.03.004
Google Scholar | Crossref | Medline6. Valentin, JP, Bass, AS, Atrakchi, A, Olejniczak, K, Kannosuke, F. Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A. J Pharmacol Toxicol Methods. 2005;52(1):22-29. doi:10.1016/j.vascn.2005.04.009
Google Scholar | Crossref | Medline7. Authier, S, Arezzo, J, Delatte, MS, et al. Safety pharmacology investigations on the nervous system: An industry survey. J Pharmacol Toxicol Methods. 2016;81:37-46. doi:10.1016/j.vascn.2016.06.001
Google Scholar | Crossref | Medline8. Authier, S, Vargas, HM, Curtis, MJ, Holbrook, M, Pugsley, MK. Safety pharmacology investigations in toxicology studies: an industry survey. J Pharmacol Toxicol Methods. 2013;68(1):44-51. doi:10.1016/j.vascn.2013.05.002
Google Scholar | Crossref | Medline9. Cochran, WG . Some methods for strengthening the common χ2 tests. Biometrics. 1954;10(4):417-451. doi:10.2307/3001616
Google Scholar | Crossref | ISI10. Sausville, EA . Chapter 30 - drug discovery. In: Atkinson, AJ, Huang, S-M, Lertora, JJL, Markey, SP, eds. Principles of Clinical Pharmacology (3rd Edition). Academic Press; 2012:507-515.
Google Scholar | Crossref11. Cha, Y, Erez, T, Reynolds, IJ, et al. Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol. 2018;175(2):168-180. doi:10.1111/bph.1379
Google Scholar | Crossref | Medline12. Schafer, KA, Eighmy, J, Fikes, JD, et al. Use of severity grades to characterize histopathological changes. Toxicol Pathol 2018; 46: 256-265.
Google Scholar | SAGE Journals | ISI13. de la Torre, BG, Albericio, F. The pharmaceutical industry in 2019. An analysis of FDA drug approvals from the perspective of molecules. Molecules. 2020;25(3):745.
Google Scholar | Crossref14. Tennant, RW, Stasiewicz, S, Eastin, WC, Mennear, JH, Spalding, JW. The Tg.AC (v-Ha-ras) transgenic mouse: nature of the model. Toxicol Pathol. 2001;29 suppl l:51-59. doi:10.1080/019262301753178474
Google Scholar | SAGE Journals15. Morton, D, Alden, CL, Roth, AJ, Usui, T. The Tg rasH2 mouse in cancer hazard identification. Toxicol Pathol. 2002;30(1):139-146. doi:10.1080/01926230252824851
Google Scholar | SAGE Journals | ISI16. ICH Guideline S11 on Nonclinical Safety Testing in Support of Development of Paediatric Pharmaceuticals. EMA. 2020. EMA/CHMP/ICH/616110/2018.
Google Scholar

留言 (0)

沒有登入
gif